In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants

In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants

Combination antiviral therapy may be helpful in the treatment of SARS-CoV-2 infection; however, no clinical trial data are available, and combined use of direct-acting antivirals (DAA) and monoclonal antibodies (mAb) has been reported only anecdotally. To assess the cooperative effects of dual drug...

Full description

Bibliographic Details
Main Authors: Lia Fiaschi, Camilla Biba, Ilenia Varasi, Niccolò Bartolini, Chiara Paletti, Federica Giammarino, Francesco Saladini, Maurizio Zazzi, Ilaria Vicenti
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Viruses
Subjects:
SARS-CoV-2
mAb
DAA
combination antiviral therapy
in vitro synergism
Omicron variant
Online Access:https://www.mdpi.com/1999-4915/16/2/168

Internet

https://www.mdpi.com/1999-4915/16/2/168

Similar Items